LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation
Just-in-time evaluation of drug resistance in situ will greatly facilitate the achievement of precision cancer therapy. The rapid elevation of reactive oxygen species (ROS) is the key to chemotherapy. Hence, suppressed ROS production is an important marker for chemotherapy drug resistance. Herein, a...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Nanomaterials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-4991/12/24/4478 |
| _version_ | 1827637492389511168 |
|---|---|
| author | Qingyuan Wang Zhizheng Zhang Dehui Qiu Xuanxiang Mao Zhaoxi Zhou Tiansong Xia Jifu Wei Qiang Ding Xiaobo Zhang |
| author_facet | Qingyuan Wang Zhizheng Zhang Dehui Qiu Xuanxiang Mao Zhaoxi Zhou Tiansong Xia Jifu Wei Qiang Ding Xiaobo Zhang |
| author_sort | Qingyuan Wang |
| collection | DOAJ |
| description | Just-in-time evaluation of drug resistance in situ will greatly facilitate the achievement of precision cancer therapy. The rapid elevation of reactive oxygen species (ROS) is the key to chemotherapy. Hence, suppressed ROS production is an important marker for chemotherapy drug resistance. Herein, a NIR-II emission smart nanoprobe (LnNP@ZIF8, consisting of a lanthanide-doped nanoparticle (LnNP) core and metal-organic framework shell (ZIF8)) is constructed for drug delivery and in vivo NIR-II ratiometric imaging of ROS for tumor drug resistance evaluation. The drug-loaded nanoprobes release therapeutic substances for chemotherapy in the acidic tumor tissue. As the level of ROS increases, the LnNPs shows responsively descending fluorescence intensity at 1550 nm excited by 980 nm (F1550, 980Ex), while the fluorescence of the LnNPs at 1060 nm excited by 808 nm (F1060, 808Ex) is stable. Due to the ratiometric F1550, 980Ex/F1060, 808Ex value exhibiting a linear relationship with ROS concentration, NIR-II imaging results of ROS change based on this ratio can be an important basis for determining tumor drug resistance. As the chemotherapy and resistance evaluation are explored continuously in situ, the ratiometric imaging identifies drug resistance successfully within 24 h, which can greatly improve the timeliness of accurate treatment. |
| first_indexed | 2024-03-09T16:01:44Z |
| format | Article |
| id | doaj.art-db94e3aa136b498990b2dfe5b0255ad3 |
| institution | Directory Open Access Journal |
| issn | 2079-4991 |
| language | English |
| last_indexed | 2024-03-09T16:01:44Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nanomaterials |
| spelling | doaj.art-db94e3aa136b498990b2dfe5b0255ad32023-11-24T17:05:02ZengMDPI AGNanomaterials2079-49912022-12-011224447810.3390/nano12244478LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance EvaluationQingyuan Wang0Zhizheng Zhang1Dehui Qiu2Xuanxiang Mao3Zhaoxi Zhou4Tiansong Xia5Jifu Wei6Qiang Ding7Xiaobo Zhang8Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, ChinaDepartment of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, ChinaState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, ChinaDepartment of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, ChinaDepartment of Pharmacy, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing 210009, ChinaDepartment of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, ChinaDepartment of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, ChinaJust-in-time evaluation of drug resistance in situ will greatly facilitate the achievement of precision cancer therapy. The rapid elevation of reactive oxygen species (ROS) is the key to chemotherapy. Hence, suppressed ROS production is an important marker for chemotherapy drug resistance. Herein, a NIR-II emission smart nanoprobe (LnNP@ZIF8, consisting of a lanthanide-doped nanoparticle (LnNP) core and metal-organic framework shell (ZIF8)) is constructed for drug delivery and in vivo NIR-II ratiometric imaging of ROS for tumor drug resistance evaluation. The drug-loaded nanoprobes release therapeutic substances for chemotherapy in the acidic tumor tissue. As the level of ROS increases, the LnNPs shows responsively descending fluorescence intensity at 1550 nm excited by 980 nm (F1550, 980Ex), while the fluorescence of the LnNPs at 1060 nm excited by 808 nm (F1060, 808Ex) is stable. Due to the ratiometric F1550, 980Ex/F1060, 808Ex value exhibiting a linear relationship with ROS concentration, NIR-II imaging results of ROS change based on this ratio can be an important basis for determining tumor drug resistance. As the chemotherapy and resistance evaluation are explored continuously in situ, the ratiometric imaging identifies drug resistance successfully within 24 h, which can greatly improve the timeliness of accurate treatment.https://www.mdpi.com/2079-4991/12/24/4478lanthanide doped nanoparticleZIF8NIR-II ratiometric imagingsmart drug delivery systemtumor drug resistance evaluation |
| spellingShingle | Qingyuan Wang Zhizheng Zhang Dehui Qiu Xuanxiang Mao Zhaoxi Zhou Tiansong Xia Jifu Wei Qiang Ding Xiaobo Zhang LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation Nanomaterials lanthanide doped nanoparticle ZIF8 NIR-II ratiometric imaging smart drug delivery system tumor drug resistance evaluation |
| title | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation |
| title_full | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation |
| title_fullStr | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation |
| title_full_unstemmed | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation |
| title_short | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation |
| title_sort | lnnp zif8 smart system for in situ nir ii ratiometric imaging based tumor drug resistance evaluation |
| topic | lanthanide doped nanoparticle ZIF8 NIR-II ratiometric imaging smart drug delivery system tumor drug resistance evaluation |
| url | https://www.mdpi.com/2079-4991/12/24/4478 |
| work_keys_str_mv | AT qingyuanwang lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT zhizhengzhang lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT dehuiqiu lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT xuanxiangmao lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT zhaoxizhou lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT tiansongxia lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT jifuwei lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT qiangding lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation AT xiaobozhang lnnpzif8smartsystemforinsituniriiratiometricimagingbasedtumordrugresistanceevaluation |